Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024 Bioxyne was hit with an impairment charge of A$11.5 million in the first half of FY24 […]
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
Company news: Cann Global; Cann Group; InhaleRx; AusCann; Wellnex Life; Neurotech; MGC Pharma; Stenocare by Martin Lane December 4, 2023April 30, 2024
Company news: Emyria; Wellnex Life; Neurotech International; Melodiol Global Health by Martin Lane November 14, 2023April 30, 2024
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Financial results: Avecho; Wellnex; Zelira; Emyria; Botanix; MGC Pharma; AusCann; Epsilon; Melodiol; Bioxyne by Martin Lane and Steve Jones September 4, 2023April 30, 2024
Wellnex Life snaps up topical pain relief brand to complement medicinal cannabis strategy by Martin Lane May 29, 2023April 30, 2024
Company news: Wellnex Life; Creso Pharma; MGC Pharma; Zelira Therapeutics by Martin Lane March 16, 2023April 30, 2024
Company news: Releaf Group; Bod; Wellnex Life; MGC Pharma; MediCann Health by Martin Lane October 27, 2022April 29, 2024
Wellnex warns of ‘limited shelf space’ as firm lays groundwork for OTC launch by Steve Jones October 6, 2022April 29, 2024
